These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34911825)

  • 1. Proceedings of the 2019 Viral Clearance Symposium, Session 6: Virus-Retentive Filtration.
    O'Donnell S; Bolton G
    PDA J Pharm Sci Technol; 2022; 76(4):349-357. PubMed ID: 34911825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proceedings of the 2017 Viral Clearance Symposium, Session 2.1: DSP Unit Operations-Virus Filtration/Inactivation.
    Kreil TR; Roush D
    PDA J Pharm Sci Technol; 2018; 72(5):470-478. PubMed ID: 30030356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of MMV as a Single Worst-Case Model Virus in Viral Filter Validation Studies.
    Gefroh E; Dehghani H; McClure M; Connell-Crowley L; Vedantham G
    PDA J Pharm Sci Technol; 2014; 68(3):297-311. PubMed ID: 25188350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proceedings of the 2017 Viral Clearance Symposium, Session 2.2: DSP Unit Operations-Purification Unit Operations.
    Roush D; Kreil TR
    PDA J Pharm Sci Technol; 2018; 72(5):479-487. PubMed ID: 30030354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virus filtration: A review of current and future practices in bioprocessing.
    Johnson SA; Chen S; Bolton G; Chen Q; Lute S; Fisher J; Brorson K
    Biotechnol Bioeng; 2022 Mar; 119(3):743-761. PubMed ID: 34936091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proceedings of the 2017 Viral Clearance Symposium, Session 1.2: Upstream Mitigation, Part 2-Virus Barrier Filter and HTST.
    Chen D; Bolton G
    PDA J Pharm Sci Technol; 2018; 72(5):462-469. PubMed ID: 30030355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achieving a Successful Scale-Down Model and Optimized Economics through Parvovirus Filter Validation using Purified TrueSpikeTM Viruses.
    De Vilmorin P; Slocum A; Jaber T; Schaefer O; Ruppach H; Genest P
    PDA J Pharm Sci Technol; 2015; 69(3):440-9. PubMed ID: 26048749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proceedings of the 2019 Viral Clearance Symposium, Session 3: Continuous Processing.
    Lute S; Specht R
    PDA J Pharm Sci Technol; 2022; 76(4):315-322. PubMed ID: 34911830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proceedings of the 2019 Viral Clearance Symposium, Session 7: Cell Banks and U.S. Pharmacopeia.
    O'Donnell S
    PDA J Pharm Sci Technol; 2022; 76(4):358-361. PubMed ID: 34911823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proceedings of the 2019 Viral Clearance Symposium, Session 1: Viral Clearance Strategies and Case Studies.
    Reitz S; Schwantes A
    PDA J Pharm Sci Technol; 2022; 76(4):297-305. PubMed ID: 34911829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meeting report--workshop on virus removal by filtration: trends and new developments.
    Willkommen H; Blümel J; Brorson K; Chen D; Chen Q; Gröner A; Kreil TR; Robertson JS; Ruffing M; Ruiz S
    PDA J Pharm Sci Technol; 2013; 67(2):98-104. PubMed ID: 23569071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proceedings of the 2017 Viral Clearance Symposium Session 5: Facility Risk Mitigation.
    Ma J; Kreil TR
    PDA J Pharm Sci Technol; 2018; 72(5):511-515. PubMed ID: 30030359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Use of Bayesian Hierarchical Logistic Regression in the Development of a Modular Viral Inactivation Claim.
    Banton D; Vacante D; Bulthuis B; Goldstein J; Wineburg M; Schreffler J
    PDA J Pharm Sci Technol; 2019; 73(6):552-561. PubMed ID: 31101710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proceedings of the 2017 Viral Clearance Symposium, Session 6: Ensuring Viral Safety in Continuous Processing.
    Johnson SA; Roush D
    PDA J Pharm Sci Technol; 2018; 72(5):516-524. PubMed ID: 30030352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A survey of quality attributes of virus spike preparations used in clearance studies.
    Miesegaes G; Lute S; Dement-Brown J; Kaushal S; Strauss D; Chen D; Brorson K
    PDA J Pharm Sci Technol; 2012; 66(5):420-33. PubMed ID: 23035026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of bacteriophages as surrogates for mammalian viruses.
    McAlister M; Aranha H; Larson R
    Dev Biol (Basel); 2004; 118():89-98. PubMed ID: 15645677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proceedings of the 2019 Viral Clearance Symposium, Session 8. Conference Summary: Key Discussion and Outcomes, Pending Questions, and Proposed Experiments and Actions.
    Bolton G
    PDA J Pharm Sci Technol; 2022; 76(4):362-367. PubMed ID: 34911826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration.
    Troccoli NM; McIver J; Losikoff A; Poiley J
    Biologicals; 1998 Dec; 26(4):321-9. PubMed ID: 10403036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a transient inline spiking system for evaluating virus clearance in continuous bioprocessing-Proof of concept for virus filtration.
    Malakian A; Jung SY; Afzal MA; Carbrello C; Giglia S; Johnson M; Miller C; Rayfield W; Boenitz D; Cetlin D; Zydney AL
    Biotechnol Bioeng; 2022 Aug; 119(8):2134-2141. PubMed ID: 35470427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biopharmaceutical Industry Approaches to Facility Segregation for Viral Safety: An Effort from the Consortium on Adventitious Agent Contamination in Biomanufacturing.
    Barone PW; Avgerinos S; Ballard R; Brussel A; Clark P; Dowd C; Gerentes L; Hart I; Keumurian FJ; Kindermann J; Leung JC; Ly N; Mink S; Minning S; Mullberg J; Murphy M; Nöske K; Parriott S; Shum B; Wiebe ME; Springs SL
    PDA J Pharm Sci Technol; 2019; 73(2):191-203. PubMed ID: 30361281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.